Taurine Eye Drops May Prevent the Progression of Cataract
NCT ID: NCT06639711
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2023-07-10
2024-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study could answer:
* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
* The acceptance/ compliance of participants to taurine-containing eye drops.
* Could long-term use of taurine-containing eye drops cause adverse effect(s)?
Participants will:
* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
* Visit eye clinic every 3 months for assessment and visual examination.
* Keep notes for their symptoms and their adherence to treatment.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Application of Taurine-containing Eye Drops
Taurine
Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Taurine
Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
* history of iritis, retinal crystalline deposits, or optic nerve disease
* visually significant fundus pathology
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Of Anbar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Atheer Zgair
Asst. Prof. Dr. Atheer Zgair
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Nahrain Eye Clinics
Ramadi, Al Anbar, Iraq
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UOANBAR-170
Identifier Type: -
Identifier Source: org_study_id